Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Abstract Background The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they may also cause genitourinary infections, polyuria,...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hiroki Nakajima, Sadanori Okada, Takako Mohri, Eiichiro Kanda, Naoyuki Inaba, Yoko Hirasawa, Hiroaki Seino, Hisamoto Kuroda, Toru Hiyoshi, Tetsuji Niiya, Hitoshi Ishii
Format: Artigo
Langue:Inglês
Publié: BMC 2018-03-01
Collection:Diabetology & Metabolic Syndrome
Sujets:
Type 2 diabetes mellitus
Oral hypoglycemic agent
Sodium glucose cotransporters 2 inhibitors
SGLT2 inhibitors
Dapagliflozin
Treatment satisfaction
Accès en ligne:http://link.springer.com/article/10.1186/s13098-018-0313-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires